Curcumin as a Holistic Treatment for Tau Pathology

Global forecasts for prevalence of Alzheimer's Disease (AD) estimate that 152.8 million people will have dementia in 2050, a sharp rise from 57.4 million in 2019 (GBD 2019). This rise can be attributable to increases in population growth and aging, but in the absence of disease-modifying therap...

Full description

Saved in:
Bibliographic Details
Main Authors: Lovesha Sivanantharajah (Author), Amritpal Mudher (Author)
Format: Book
Published: Frontiers Media S.A., 2022-05-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_7c97bc61f61c413eb215e18a1cbac83d
042 |a dc 
100 1 0 |a Lovesha Sivanantharajah  |e author 
700 1 0 |a Amritpal Mudher  |e author 
245 0 0 |a Curcumin as a Holistic Treatment for Tau Pathology 
260 |b Frontiers Media S.A.,   |c 2022-05-01T00:00:00Z. 
500 |a 1663-9812 
500 |a 10.3389/fphar.2022.903119 
520 |a Global forecasts for prevalence of Alzheimer's Disease (AD) estimate that 152.8 million people will have dementia in 2050, a sharp rise from 57.4 million in 2019 (GBD 2019). This rise can be attributable to increases in population growth and aging, but in the absence of disease-modifying therapies it poses a huge societal challenge that must be addressed urgently. One way to combat this challenge is to explore the utility of holistic treatments that may protect against AD, including traditional herbs, spices and other nutraceuticals that are pharmacologically safe, inexpensive and readily available. In this light, the spice turmeric, and its active ingredient curcumin, has been investigated as a potential holistic treatment for AD over the past 2 decades; however, promising results with animal studies have not translated to success in clinical trials. One issue is that most animal models examining the effects of curcumin and curcumin derivatives in AD have been done with a focus at ameliorating amyloid pathology. Due to the limited success of Amyloid-β-based drugs in recent clinical trials, tau-focused therapeutics provide a promising alternative. In this article, we aim to provide a clearer picture of what is currently known about the effectiveness of curcumin and curcumin derivatives to ameliorate tau pathology. Tau focused studies may help inform more successful clinical studies by placing greater emphasis on the development and optimised delivery of curcumin derivatives that more effectively target tau pathology. 
546 |a EN 
690 |a turmeric (Curcuma longa L) 
690 |a curcumin 
690 |a Alzheheimer's disease 
690 |a tauopathy 
690 |a animal models 
690 |a holistic medicine 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Frontiers in Pharmacology, Vol 13 (2022) 
787 0 |n https://www.frontiersin.org/articles/10.3389/fphar.2022.903119/full 
787 0 |n https://doaj.org/toc/1663-9812 
856 4 1 |u https://doaj.org/article/7c97bc61f61c413eb215e18a1cbac83d  |z Connect to this object online.